Safety and efficacy of allogeneic bone as a bone filling material for sinus floor augmentation

Ohba Seigo0 个研究点目标入组 10 人开始时间: 2021年8月27日最近更新: 2023年10月17日

试验速览

暂无简介。

•1. Patients who have a preference to receive a dental implant treatment for missing tooth in the maxillary posterior region.
•2. Patients whose alveolar bone volume are insufficient for ideal implant placement, and are required the sinus floor augmentation for the dental implant placement.
•3. Patients who can personally provide written consent at their own free will after being receiving a thorough explanation of the study and fully understanding their participation in the study.

•1. Patients with problem in judgement.
•2. Patients with drug hypersensitivity such as allergy.
•3. Women who are or may be pregnant or lactating women.
•4. Patients who are participating in another clinical study.
•5. Patients are immunocompromised with severe diabetes or severe liver or renal dysfunction.
•6. Patients with severe peptic ulcer or cardiovascular or respiratory diseases and disorders,
•7. Smokers
•8. Patients receiving therapies with anti-resorption drugs such as bisphosphonate which affect bone metabolism .
•9. Partients who are judged to be inappropriate to participate the study by the principal or cooperative doctors.

发起方

Ohba Seigo